Portfolio | 奕安济世顺利完成B+轮3500万美元融资

2018年 6 月6日，中国，杭州 - 致力于开拓全球抗体和重组蛋白类生物药治疗领域的奕安济世生物药业(Hangzhou Just Biotherapeutics Inc., 简称“奕安济世”) 今日宣布顺利完成3500万美元的B+轮融资。此次B+轮由高瓴资本领投，现有股东淡马锡、礼来亚洲基金、ARCH Venture Partners、泰康及中银浙商共同出资完成。包括此轮融资在内，奕安济世从创立至今融资总额已超过1.4亿美元（约合10亿人民币）。

“在短短不到两年的时间中，奕安济世已在多个重要发展节点上顺利实现了我们的既定目标，并将继续这一迅猛发展的势头”，奕安济世创始人和总裁赵奕宁博士表示，“B+ 轮融资将帮助我们更好地提升全球研发实力，并通过构建更广泛的业务合作关系，全面推进产品管线的开发。今年，奕安济世的多款一类创新药物将在全球开展临床试验”。

本轮的领投机构高瓴资本表示：“创新医药的发展能够切实为社会创造价值，服务海内外患者，有广阔的市场成长空间。高瓴历来重视医药行业的研发和创新，我们看好奕安济世在生物制药领域的实力和前景，愿意用价值投资的理念和方式支持公司长远发展。”

2016 年，奕安济世由原美国安进 (Amgen) 和基因泰克公司 (Genentech) 的资深专家创立。作为一家以先进的生物工艺技术为平台的创新型公司，奕安济世设计并运用先进的抗体和重组蛋白工艺进行研发和生产，通过应用灵活性生产技术，研发符合国际质量标准的生物医药，显著加速研发进程，并大幅降低生产成本。

目前，奕安济世在全球已拥有近百位科研人员和生物工程师，管理团队中更是拥有两位入选国家“千人计划”及两位入选浙江省“千人计划”的专家。奕安济世具备完整的临床开发和生产体系，并在杭州和波士顿分别设有研发和生产基地。奕安济世目前产品管线涵盖肿瘤、遗传性罕见病和代谢病领域，此次 B+ 轮融资的资金将主要用于加速全球临床试验进程。

关于高瓴资本

高瓴资本是一家专注于长期结构性价值投资的公司，由张磊先生于2005年创立，经过十余年的发展，已成为中国最大的私募股权投资机构。高瓴资本的投资覆盖医疗健康、消费零售、TMT、先进制造、金融及企业服务等领域，代表性的投资案例包括：腾讯、百度、京东、美的、蓝月亮、百丽国际和蔚来汽车等。生物医药和医疗健康行业始终是高瓴的重点投资方向。高瓴致力于做创新药研发企业的全程投资人，支持了国内外很多优秀的医药企业，例如药明康德、百济神州、甘李药业、君实生物、信达生物和海正辉瑞等，还包括以Moderna、Viela、Kiniksa、Apellis和Arcus为代表的美国和欧洲几十家生物制药企业。

欲了解更多高瓴资本的相关信息，请登陆 www.hillhousecap.com

关于奕安济世

奕安济世致力于生物药物分子设计、连续化工艺开发再到规模连续生产，来解决或消除抗体高效开发和降低生产成本的一系列技术障碍，为全球更多患者创造价值。目前，奕安济世在杭州拥有研发中心及生产基地，并在美国波士顿设立了临床开发部。

欲了解更多奕安济世的相关信息，请登陆 www.justbiochina.com

附英文新闻：

Hangzhou Just Biotherapeutics Secures $35 Million Series B+ Financing

To enhance R&D capabilities and accelerate clinical trials globally

Hangzhou, China, June 6, 2018 - Dedicated to developing global antibody and recombinant protein biotherapeutics, Hangzhou Just Biotherapeutics (HJB) announced today the completion of a $35 million Series B+ financing round.

Hillhouse Capital (Hillhouse), a Beijing and Hong Kong-based investment firm, leads the financing, with participation by existing investors Temasek,  Lilly Asia Ventures (LAV), ARCH Venture Partners, Taikang, and BOCGI Zheshang Capital. Including this round, HJB has secured over $140 million in financing.

In the last year, HJB has focused predominantly in 3 areas: The completion of the R&D Center and Manufacturing Facility located in Hangzhou, establishing its R&D and clinical development capabilities and building a world-class team by attracting top talent around the world.

“We have achieved remarkable milestones in a short time, but we need to continue to build on our successes. With this additional investment, we will be able to ramp up our R&D capabilities globally, and boost our pipeline by engaging in broader partnerships. We are now on our way to beginning clinical trials for several of our assets, ” said Dr. Yining ZHAO, co-founder and CEO of HJB.

As the lead investor, Hillhouse Capital said, “Innovative medicine has great market growth potential because it can truly create value for society, serving patients in and outside China. Hillhouse has always valued medical research and innovation. We appreciate HJB’s capabilities and promising future in the field of bio-pharmaceutical research and development and are willing to support the firm’s long-term growth using the principles and methods of value investing.”

HJB was founded in 2016 as a joint venture with Seattle-based Just Biotherapeutics, Inc. (Just) by four former Amgen executives. The company’s state-of-the-art biomanufacturing and process development platform enables it to develop and manufacture antibody and recombinant proteins at a reduced cost and accelerated speed while maintaining global quality standards. The company’s core strengths lie in the design process, which can be deployed throughout the biotherapeutic life cycle, from molecular design all the way to drug product. HJB’s pipeline currently consists of assets in areas of high-unmet need including immunology, hematology and metabolism. HJB employs a team of over one hundred scientists and engineers at its sites in China and US, and is led by seasoned executives from Amgen, Sanofi, Tensha, Genentech and Novartis.

About Hillhouse Capital

Hillhouse Capital Group (Hillhouse) is a company dedicated to long-term value investing. Founded by Lei Zhang in 2005, it has grown to be China’s biggest private equity investment company. Hillhouse focuses on the healthcare, consumer, TMT, advanced manufacturing, finance and corporate services sectors, and has invested in many household names in China including Tencent, Baidu, JD.com, Midea, Blue Moon, Belle International and Nio. Bio-pharmaceuticals and healthcare has always been one of our most important areas of investment. Aiming to be a long-term partner with companies developing innovative medicine, Hillhouse has invested in and supported a number of medical enterprises, including Wuxi Apptec, BeiGene, Gan & Lee Pharmaceuticals, Shanghai Junshi Biosciences, Innovent Biologics and Zhejiang Hisun Pharmaceutical. In Europe and the United States, we have invested in Moderna, Viela, Kiniksa, Apellis and Arcus, among other dozens of biotechnology and pharmaceutical companies.

For more information, please refer to www.hillhousecap.com.

About Hangzhou Just Biotherapeutics

Hangzhou Just Biotherapeutics (HJB) is a biotherapeutics platform company that integrates the design, development and manufacture of biologics. With deep experience in the fields of protein, process and manufacturing sciences, the HJB team came together to solve the scientific and technical hurdles that block access to life changing protein therapeutics; from the design of therapeutic molecules to the design of the manufacturing plants used to produce them. Our focus and passion is to create access and value for a global market through scientific and technological innovation. 

For more information about HJB, please visit www.justbiochina.com.

近期文章

Portfolio公司新闻

行业趋势

原创